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Summary Natural killer (NK) cells are involved in the antitumoral immunologic mechanism. These cells act
through the release of cytotoxic molecules defined as NK cytotoxic factors (NKCF). Inhibitory factors of NK
and NKCF mediated lysis have been described in in vitro assays. This study evaluates the induction of
resistance to NKCF cytotoxicity by sera from 27 patients with colon, breast and lung cancer. Addition of
these sera to the cytolytic assay where K562 cells and concentrated NKCF were used, induced resistance to
NKCF mediated cytotoxicity in 21 cases (77%). The sera from the group with metastasis blocked NKCF lysis
more markedly than the group with local tumours. However, no differences were observed when the groups
with colon, breast and lung cancers were compared. This blocking effect was not found to be related to
gamma interferon (IFN) levels. In a previous study, we described a tumour factor (NK-RIF) produced by
human cell lines derived from metastatic adenocarcinomas. This factor blocked lysis of tumour target cells by
NK cells. Consequently, it is proposed that the release of similar tumour factors with a capacity to induce
resistance to NKCF may be involved in tumour growth and metastatic spreading in in vivo.
Natural killer (NK) cells have been implicated in the control
of distant metastatic diseases (Herberman & Holden, 1978;
Trinchieri & Perussia, 1984). They have been defined as a
subset of peripheral blood lymphocytes with distinctive mor-
phological, phenotypic and functional characteristics. NK
cells display the structural features of large granular lympho-
cytes (LGL) (Grossi et al., 1978, 1982; Saksela et al., 1979;
Timonen et al., 1981) and the ability to lyse a variety of
neoplastic and non-neoplastic target cells, including virus-
infected ones and hematopoietic precursors (Herberman et
al., 1982, 1986; Trinchieri & Perussia, 1984). NK cells from
human, rat or mouse, release natural killer cytotoxic factors
(NKCF), functionally defined as lymphokines selectively
cytotoxic for NK target cells (Herberman et al., 1979, 1986;
Savary & Lotzova, 1986).
The mechanisms involved in the resistance or susceptibility
of tumour cells to NK cells are poorly understood (Stern et
al., 1980; Powel et al., 1987; Harris et al., 1987; Pefia et al.,
1990a,b), but studies have demonstrated that natural killer
cell activity is diminished in colon, breast and lung cancer,
especially in advanced stages or in those with metastatic
processes (Lin et al., 1987; Tartter et al., 1987; Hisamatus et
al., 1986). Thus, the deficient activity of NK cells results in
increased numbers of metastasic deposits and tumoral escape
from immunologic vigilance (Schantz et al., 1986).
We have recently described a factor (NK-RIF) released by
cell lines with adenocarcinoma metastasis and which induces
resistance of K562 cells to NK mediated lysis by blockage of
NKCF activity without affecting target and effector con-
jugate formation (Serrano et al., 1989; Solana et al., 1990a,b).
It does not interfere with macrophage, lymphokine activated
killer (LAK) or T cytotoxic cell mediated lysis. Considering
the possibility that tumour cells release this factor or others
with similar activity in vivo, this paper studies the presence of
NK-RIF like activity in sera from patients with colon, breast
and lung adenocarcinomas. The capacity of these sera to
induce resistance of K562 cells to lysis by NKCF obtained
from normal donors was tested. This can be of biological
interest and useful in clinical diagnosis and prognosis.
Materials and methods
Patient sera
Sera were obtained from 27 patients from the Oncology
Service-General Hospital- aliquotes and stored at - 70'C
until further use. Primary disease site was colon in ten
patients, breast in 12 and lung in five. At the time of sera
collection, five patients had no clinical or pathological evi-
dence of metastatic dissemination, 11 had clinical metastasis
and 11 had undergone surgical extirpation of the primary
tumour. The stage of the disease and other relevant charac-
teristics are shown in Table I. Control sera were obtained
from age and sex matched normal blood donors.
Table I Patient profile study
Primary
Patient tumour Tumour stage Tumour location
1 Breast IV Lung and liver metastasis
2 Breast IV Lung and liver metastasis
3 Colon B - Dukes Local
4 Colon D - Dukes Lung and liver metastasis
5 Breast III Local
6 Breast IV Bone metastasis
7 Lung IV Kidney metastasis
8 Breast IV Bone metastasis
9 Colon D - Dukes Liver metastasis
10 Lung III Local
11 Colon D - Dukes Lung and liver metastasis
12 Colon D - Dukes Liver metastasis
13 Lung III Local
14 Breast III Extirpated
15 Colon B - Dukes Extirpated
16 Breast III Extirpated
17 Breast II Extirpated
18 Breast II Extirpated
19 Colon A - Dukes Extirpated
20 Colon D - Dukes Extirpated
21 Colon C - Dukes Extirpated
22 Breast III Extirpated
23 Lung IV Brain metastasis
24 Breast II Extirpated
25 Colon D - Dukes Liver metastasis
26 Lung I Local
27 Breast II Extirpated
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Cell line
Cell line K562 were grown in RPMI 1640 supplemented with
10% heat inactivated foetal calf serum, 2 mM L-glutamine,
100Uml-' penicillin and 50p1gmlm' gentamycin at 37°C in
5% CO2.
Production ofNKCF
NKCF was prepared as previously described (Solana et al.,
1990a). Briefly, cell free supernatants were generated by
incubating NK effector cells obtained from normal volun-
teers 2 x 106 with K562 (effector-target ratio 50:1) in serum
free medium. After 48 h of incubation at 37°C in 5% CO2 air
atmosphere, the cultures were centrifuged at 400g for 10 min
and the supernatants collected and filtered through a 0.22 gLm
Millipore filter. The supernatants were concentrated ten times
with a Minicon B15 microconcentrator and stored at - 7OC
until further use.
NKCFmediated chromium release assay
K562 target cells (106ml-') were incubated with 1 mCi of
sodium 5"CrO4 for 1 h. After washing three times, 104 labelled
cells in 50jil were used as targets in a cytotoxicity assay by
adding 50 tl of patient serum and 50yl of NKCF. The
cytotoxicity assay was performed in triplicate in 96 U-round-
bottomed well plates. For spontaneous and total release,
samples of target cells were resuspended in culture medium
and 10% triton X-100 (final volume 150 1Al), respectively.
Controls with target cells, NKCF and culture medium and
controls with target cells, NKCF and serum from age and
sex matched healthy donors were always included. Cells were
incubated for 24 h at 37TC in 5% CO2. Supernatants (100fil)
were then collected and counted in a gamma counter (Ultra-
gamma LKB). Specific lysis was determined with the follow-
ing equation:
(problem c.p.m.-spontaneous c.p.m.) % lysis =~ x 1 00
(total c.p.m.-spontaneous c.p.m.)
Specific lysis was not significantly affected by the addition
of control sera. The specific lysis of controls without serum
or with control sera ranged from 10% tol7% in the different
experiments (mean ± s.e.m.: 14% ± 1%). Individual inhibi-
tion percentages were calculated as follows:
% lysis with patient serum
% lysis with control serum
Each sample was tested in three independent experiments
and variations never exceeded 15% inhibition.
Determination ofgamma interferon levels
The IFN levels were determined by a two-site immunoradio-
metric assay - IRMA (Sucrosep Boots-celltech diagnostic
limited, Berkshire, UK). Concentrations were quantified
directly by incubation with an '251I-labelled antibody complex
which was then immobilised by incubation with a sheep
anti-aIFN antibody coupled to the solid phase. In our experi-
mental conditions the assay had a minimum sensitivity of
Table II Relationship between the stage ofthediseaseand the number
of patient's sera presenting blockage or non-blockage of NKCF
cytotoxicity
Blockagea Non-blockage
Tumour Colon Breast Lung Total
Without 2/2 5/3 1/2 8/7
metastasis
With 5/1 4/0 2/0 11/1
metastasis
Total 7/3 9/3 3/2
aBlockage was defined as more than 90% inhibition of NKCF
cytotoxicity.
4 Uml1' and values below this concentration were con-
sidered not detectable.
Statistical methods
Comparisons between groups were based on Student t-test.
Results
Serafrompatients with metastasis block NKCFcytotoxicity
significantly more than serafrom those with localgrowth
tumours
We divided neoplasm patients according to the degree of
tumour invasion and results show that 11 out of 12 with
metastasis (stage IV/D) had a blocked capacity of NKCF
lysis while only half of the patients without metastasis (stages
I/A, II/B and III/C) presented the same capacity (Table II).
Moreover, when the intensity of the inhibitory activity was
analysed, we found that this was different in the group with
metastasis when compared to the non-metastasis one. Sera
from patients without metastasis slightly blocked NKCF
mediated lysis (mean ± s.e.m.: 26% ± 16% blockage) where-
as sera from patients with metastasis markedly inhibited
NKCF lysis (mean ± s.e.m.: 65% ± 9%) (Figure 1).
The group with extirpated tumours showed heterogeneous
results with respect to the blockage of NKCF cytotoxicity
which cannot be either attributed to the time past since
surgery (Table III) or to possible microneoplasm remaining
in these patients once we analysed their current clinical situa-
tion.
No differences were observed in tumour origin
NKCF cytotoxicity was blocked in seven out of 10, nine out
of 12 and three out of five colon, breast and lung cancers,
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Figure 1 Mean±s.e.m. of the inhibitory intensity of NKCF
mediated cytotoxicity by sera from patients with (n = l1) or
without mestatasis (n = 5). The difference between the two groups
is significant according to Student t-test.INDUCTION OF RESISTANCE TO NKCF 895
Table III Relationship between percentage ofblockage in extirpated
breast and colon cancer and the time since surgery
Site ofdisease Months since surgery % Blockage
Colon 1
Breast 1 100
Colon 2 45
Colon 3 100
Colon 5
Breast 8 100
Breast 9 67
Breast 9 35
Breast 10 41
Breast 13
Breast 15
non-blockage.
respectively, demonstrating that the site of the primary
disease is not the main factor determining the capacity of
these sera to inhibit NKCF cytotoxicity (Table II).
The blockage effect to NKCF cannot be attributed to aIFN
As previously reported, treatment with aIFN can also induce
resistance to NKCF lysis, thus, we also measured aIFN
levels in sera from these patients. Most of them (24/27) had
detectable levels of interferon while it was not detectable in
controls (Table IV). We suggest that the high levels of serum
interferon in these subjects is a consequence of the immuno-
logic response of the host organism to neoplasm. However,
NKCF blockage cannot be attributed to the presence of
IFN, as it appears in all the stages of the disease regardless
of the induction of resistance to NKCF cytolysis.
Discussion
Several hypothesis explaining NK resistance of different
tumour cells have been suggested. These include, for
example, a defect in the recognition of target cells with a
relationship between HLA antigen expression and tumour
cell performance (Stern et al., 1980; Karre et al., 1986; Powel
et al., 1987; Rodger et al., 1988; Alonso et al., 1989; Ljnggren
& Karre, 1990; Solana et al., 1990b; Peiia et al., 1990a,b); a
resistance of target cells to lytic factors such as TNF or
NKCF produced by immunocompetent cells (Roozemond et
al., 1987); or an inhibited NK activity owing to tumour
suppressor factors or peptides such as prostaglandin E2 and
NK-RIF (Harris et al., 1987; Serrano et al., 1989, 1990;
Solana et al., 1990a). However, the exact mechanisms by
which NK cells interact with target cells remains unclear. The
different roles that the molecules play on the target cell
surface such as recognition elements by NK effectors have
been postulated (Vodilenich et al., 1983; Hercend et al., 1984;
Natuk & Welsh, 1987; Johnson et al., 1987).
Many authors have reported diminished NK activity in
different experimental models and in patients with tumours
with different stages of the disease (Hisamatsu et al., 1986;
Schantz et al., 1986; Wei & Heppner, 1987; Lin et al., 1987;
Tartter et al., 1987). Cells from freshly explanted solid
tumours are resistant to NK mediated lysis and the causes
determining NK resistance are not clearly understood.
The presence of factors in sera from tumours patients
inhibiting NK cytotoxicity has been described, although
results are not conclusive (our unpublished results; Brenner et
al., 1986). This is probably due to the presence in this sera of
a variety of factors such as aIFN which has a dual effect on
NK lysis, either activating NK cells (Herberman et al., 1986)
or inducing NK resistance in several target cells (Ramirez et
al., 1990). Thus, in order to find an experimental system
where only the inducation of resistance to lysis is evaluated,
we studied the capacity of sera from tumour patients to
block lysis of K562 cells by concentrated NKCF.
The analysis of 27 sera from patients with colon, breast
and lung cancer demonstrated that 10/11 from metatatic and
2/5 from local disease had the capacity to block NKCF
mediated cytotoxicity of NK target cell line K562. This
capacity was not related to the stage of the disease, but only
to the presence of the metastasis.
Although a number of tumour factors have been defined to
inhibit NK cell activity, the induction of NK resistance has
been related mainly to the activity aIFN and a new tumour
growth factor, released in vitro by tumour cell lines from
metastatic adenocarcinomas, defined as NK-RIF (NK-resist-
ance inducing factor). Both make K562 cells resistant to NK
and NKCF lysis. Moreover, NK-RIF does not affect LAK,
macrophage and T cells mediated cytotoxicity nor conjugate
formation between the NK effector and target cells (Serrano
et al., 1989, 1990; Solana et al., 1990a,b).
Other proteins such as x2-macroglobulin or non-specific
proteases may also participate in the blockage observed by
neutralising with NK cytotoxic factors before they can lyse
the target cells as they interact with other lymphokines
(James, 1990).
When we studied the presence of aIFN in these patients,
our results showed high levels of aIFN in most of them. No
significant relationship between aIFN levels and the degree of
NKCF lysis blockage were found, suggesting that it is not
the main agent responsible for the induction of NKCF resis-
tance.
In conclusion, although further studies on the molecular
definition of this activity are required, the data presented
show that sera from patients with metastatic cancers induce
resistance to K562 to NKCF lysis and suggest that molecules
that induce NK resistance can be produced in vivo by meta-
static neoplasm cells. These results prompt the possibility
that the release of NK-RIF like factors facilitate tumour
growth and the spread of neoplasm, allowing tumour cells to
evade the host resistance mechanisms. Investigations leading
to the understanding of the mechanisms involved in NK
resistance induced by tumours factors will lead to a better
Table IV Relationship between the stage of the disease and aIFN level
Colon Breast Lung
Disease IFN level Disease IFN level Disease IFN
Patient stage Patient stage Patient stage level
19 A 14 17 II - 26 I 70
3 B 37 18 II 52 10 III 60
15 B 44 24 II 38 13 III 40
21 C 38 27 II 40 7 IV 53
4 D 60 5 III 65 23 IV 49
9 D 64 14 III 47
11 D 43 16 III 60
12 D 44 22 III 38
20 D 52 1 IV 61
25 D 39 2 IV -
6 IV 47
8 IV -
non-detectable level. Measured in Uml-'.8% M. MARUBAYASHI et al.
knowledge of the NK-tumour cell interaction and will contri-
bute to a better evaluation of the diagnosis and prognosis of
cancer patients.
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